NCT03372200View on ClinicalTrials.gov

Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout

PHASE3CompletedINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

January 9, 2018

Primary Completion Date

June 4, 2018

Study Completion Date

July 5, 2018

Conditions
Hyperuricemia With or Without Gout
Interventions
DRUG

FYU-981

Oral daily dosing for 14 weeks

DRUG

Febuxostat

Oral daily dosing for 14 weeks

Trial Locations (1)

Unknown

Mochida Investigational sites, Tokyo

Sponsors

Collaborators (1)

Fuji Yakuhin Co., Ltd.
All Listed Sponsors
collaborator

Fuji Yakuhin Co., Ltd.

INDUSTRY

lead

Mochida Pharmaceutical Company, Ltd.

INDUSTRY

NCT03372200 - Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout | Biotech Hunter | Biotech Hunter